Wolters Kluwer Health and the European Society of Oncology Pharmacy (ESOP) today announced the launch of a new open access journal, the European Journal of Oncology Pharmacy (EJOP).The official journal of the ESOP will join the Lippincott portfolio and is open for submissions beginning August 29, 2017.
EJOP is a peer-reviewed pharmaceutical journal in the field of cancer treatment.Under its scope, the journal will focus on the role of pharmacists in the prevention and treatment of cancers.This includes basic and applied research on the synthesis or extraction, compounding, analysis, stability, pharmacology,side-effects and clinical use of anticancer drugs and adjuvants therapies such as antiemetic, analgesic or complementary medicines.
“I am convinced that EJOP should be the journal of reference for pharmacists working in the field of oncology. However, we believe that EJOP could also be an excellent multidisciplinary publication platform for those interested in all the aspects of the pharmacological approach to cancer treatment,” said Professor Alain Astier, Editor-in-Chief, University Hospital Henri Mondor, Paris 12 University. “Our editorial board is constituted of recognized worldwide specialists from all the major fields of oncology pharmacy, thus guaranteeing the highest quality of the published papers.”
Authors are encouraged to share their ideas and valuable research outcomes through EJOP and provide its global readers with updated and important information through original articles, review articles, case reports, short communications, etc. Of particular interest are articles discussing the multi- professional approaches of patient care.
The journal will open for the peer review of manuscripts on August 29. All manuscripts must be submitted online at: www.editorialmanager.com/ejop.
